Story Highlight
– Carole Bianchi diagnosed with meningioma after severe headaches.
– Benign tumor linked to long-term use of Depo-Provera.
– Women report life-altering effects from the contraceptive.
– Lawsuits against Pfizer expected to increase significantly.
– Official guidance warns of potential brain tumor risk.
Full Story
Carole Bianchi’s life drastically changed when she began experiencing debilitating headaches that left her incapacitated for days. Initially, doctors struggled to determine the origin of her pain, and for four months, she was treated with steroids aimed at reducing swelling. It wasn’t until her GP referred her for a CT scan that the cause was identified: a meningioma, a benign and slow-growing tumour. Carole believes that this condition may be linked to her use of the contraceptive Depo-Provera, which she had taken for a decade.
Now, three years post-diagnosis and after a complicated six-hour operation, Carole’s existence has been irreversibly altered. The health care assistant from Wiltshire has lost much of her self-confidence following the diagnosis, suffering from severe anxiety and depression. Additionally, she now grapples with the permanent loss of her sense of smell. Her life took a dramatic turn after she watched a television report in June that discussed the potential correlation between Depo-Provera and the development of brain tumours. “I was shocked and baffled,” Carole, now 50, remarked about her realisation.
In recalling the harrowing experience surrounding her diagnosis, Carole vividly remembers the moment the medical staff informed her of the tumour. Located at the front of her brain and described as being the size of a ping-pong ball, it was deemed calcified, implying it may have been growing for a considerable time. “I was shocked and very frightened – I thought I was going to die,” she said.
The surgical procedure at John Radcliffe Hospital in February 2023 aimed to remove the mass but resulted in lasting effects, including numbness in her scalp and partial palsy affecting her eyebrow. Carole began using Depo-Provera at the age of 30, initially to manage heavy menstrual periods. This contraceptive, administered via injection every three months, is used by approximately 74 million women around the globe, with roughly 3.1 per cent of women in the UK opting for it.
However, a study published in the British Medical Journal in 2024 indicated that women using Depo-Provera for 12 months or longer are nearly six times more likely to be diagnosed with brain tumours. This study prompted an update to the patient information leaflet issued by UK medical regulators and Pfizer, which highlights the risks associated with its use. Pfizer maintains that they conduct “rigorous and continuous monitoring” and assert the safety of Depo-Provera.
In light of these findings, Carole, alongside many others, is seeking accountability. She is contemplating joining a class action lawsuit against Pfizer being spearheaded by solicitors from Austen Hays. “It feels to me like a time-bomb lottery for many women regularly using Depo-Provera right now, even for those who stopped a while ago,” Carole stated. Although official guidelines deem the risk of developing a meningioma while using this contraceptive to be relatively low, reports of cases, including her own, cannot be overlooked.
Over 1,000 women in the United States have initiated lawsuits against Pfizer seeking compensation, and projections suggest that this number may expand from 5,000 to 10,000, with potential claims reaching several billion dollars. Meanwhile, the NHS advises that “having medroxyprogesterone contraceptive injections for three years or longer may also increase your chance of getting a type of brain tumour called meningioma,” although it reassures that such tumours are still classified as rare.
Carole continues to face profound changes in her lifestyle, expressing her sentiments about the “new” version of herself. “I miss being able to smell sweet things; I even dream of flowers sometimes and feel so happy until I wake up,” she shared. The stark contrast she sees in her life is apparent: “There was the old me, more confident and girly, and now, I am a different person.” While Pfizer has amended product labelling to indicate the associated risks, many believe this action comes too late for those affected.
Carole’s experience resonates with that of Claire Buck, a 47-year-old from Surrey. Like Carole, Claire began using Depo-Provera in 2014. She too suffered from excruciating headaches, which escalated over time, leading to a meningioma diagnosis in 2023. The surgery to remove the tumour resulted in facial and scalp disfigurement as well as muscle shrinkage, complicating her ability to care for others and maintain her independence.
Another individual, Liz Granville, started using Depo-Provera a decade ago, stopping only after discovering its links to brain tumours. Liz eventually received a diagnosis of two tumours pressing against her skull that have caused seizures, leading to a complete upheaval in her life. “I can’t drive, I can’t work,” Liz lamented, reflecting on the substantial changes that have disrupted her routine as a single mother.
Dr Alison Cave, Chief Safety Officer for the Medicines and Healthcare products Regulatory Agency (MHRA), stated, “For the majority of people, the benefits of Depo-Provera outweigh the risks, but we advise anyone with concerns to speak with their GP.” She added that they would evaluate the need for further action should significant new information emerge.
Patrick McGuire, senior partner with Thompsons Solicitors Scotland, leading the class action against Pfizer, described the scope of the situation as “truly shocking.” He called for a comprehensive public inquiry by the UK Government to address these alarming allegations and ensure the safety of women using Depo-Provera.
Our Thoughts
The case of Carole Bianchi highlights several critical areas where improvements could have been made to prevent the severe health consequences associated with the use of Depo-Provera. Enhanced monitoring and communication regarding long-term risks associated with medications are essential. It appears that key safety information regarding the potential link between Depo-Provera and meningiomas only became widely known after significant delays, likely breaching the Health and Safety at Work Act 1974, which mandates that employers ensure, as far as is reasonably practicable, the health and safety of employees and relevant parties.
The updated patient information leaflet indicates a regulatory response but came too late for many affected individuals. The Medicines and Healthcare products Regulatory Agency’s (MHRA) proactive monitoring system should be improved to include more rigorous studies and timely updates on potential risks.
To prevent similar incidents, it is imperative for healthcare providers to have robust systems in place for regularly reviewing the safety profiles of long-term medications and ensuring that patients are adequately informed about emerging risks. Regular training on updated safety information should be mandated for healthcare professionals to ensure that patients receive comprehensive counseling regarding their treatment options.
